礼来下一代减重针再过关
2026-07-23 10:45:54
据彭博社报道，礼来公司表示，其备受期待的下一代减重针在一项新研究中未增加整体心脏风险，缓解了外界对其潜在风险的持续担忧，并临近监管审查。
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
礼来推迟申报减重药retatrutideNext article：
希思罗机场转机客增加
